BRPI0618399A2 - região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico - Google Patents
região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico Download PDFInfo
- Publication number
- BRPI0618399A2 BRPI0618399A2 BRPI0618399-9A BRPI0618399A BRPI0618399A2 BR PI0618399 A2 BRPI0618399 A2 BR PI0618399A2 BR PI0618399 A BRPI0618399 A BR PI0618399A BR PI0618399 A2 BRPI0618399 A2 BR PI0618399A2
- Authority
- BR
- Brazil
- Prior art keywords
- isolated
- antigen binding
- binding region
- specific
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
Abstract
REGIAO DE LIGAçãO DE ANTìGENO ISOLADA QUE é ESPECìFICA PARA CD38, ANTICORPO ISOLADO OU UM FRAGMENTO FUNCIONAL DO MESMO QUE é ESPECìFICO PARA CD38, ANTICORPO ISOLADO OU UM FRAGMENTO FUNCIONAL DO MESMO, IMUNOGLOBULINA ISOLADA, CADEIA PESADA VARIáVEL DE UMA REGIAO DE LIGAçAO DE ANTìGENO ISOLADA, CADEIA LEVE VARIáVEL DE UMA REGIAO DE LIGAçAO DE ANTìGENO ISOLADA, SEQUêNCIA ISOLADA DE áCIDO NUCLéICO, SEQUêNCIA DE áCIDO NUCLéICO QUE CODIFICA UMA CADEIA PESADA VARIáVEL DE UMA REGIAO DE LIGAçAO DE ANTìGENO ISOLADA, SEQUêNCIA DE áCIDO NUCLEICO, VETOR, CéLULA ISOLADA, COMPOSIçAO FARMACêUTICA, USO DA COMPOSIçAO FARMACêUTICA, MéTODO DE INDUçAO DE MORTANDADE ESPECìFICA DAS CéLULAS DE TUMOR QUE EXPRESSAM CD38, MéTODO DE DETECçAO DA MORTANDADE ESPECìFICA DAS CéLULAS DE TUMOR QUE EXPRESSAM CD38, MéTODO DE DETECçAO DA PRESENçA DE CD38 EM UM TECIDO OU EM UMA CéLULA DE ORIGEM DE MINIPORCO, MéTODO DE DETECçAO DE CD38 EM UM ERITRóCITO QUE EXPRESSA CD38 E COMPOSIçAO DE DIAGNóSTICO A presente invenção apresenta novos anticorpos e métodos para a utilização de regiões de ligação de antígenorecombinante e anticorpos e fragmentos funcionais que contêm tais regiões de ligação de antígeno que são específicas para CD38, que desempenha um papel integral em vários distúrbios ou condições. Esses métodos se beneficiam dos anticorpos recentemente descobertos e das propriedades surpreendentes de tais anticorpos, tais como a capacidade de se ligar ao CD38 de origem de miniporco e a capacidade de induzir, por reticulação, uma mortandade específica de células que expressam CD38. Esses anticorpos, bem como os novos métodos para a utilização desses anticorpos, podem ser utilizados para o tratamento, por exemplo, de malignidades hematológicas tais como o mieloma múltiplo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72529705P | 2005-10-12 | 2005-10-12 | |
| US60/725,297 | 2005-10-12 | ||
| PCT/EP2006/009889 WO2007042309A2 (en) | 2005-10-12 | 2006-10-12 | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0618399A2 true BRPI0618399A2 (pt) | 2011-08-30 |
| BRPI0618399B1 BRPI0618399B1 (pt) | 2023-10-03 |
Family
ID=37467440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0618399-9A BRPI0618399B1 (pt) | 2005-10-12 | 2006-10-12 | Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US8088896B2 (pt) |
| EP (3) | EP2860192B1 (pt) |
| JP (2) | JP5362359B2 (pt) |
| KR (4) | KR101472250B1 (pt) |
| CN (4) | CN101287764B (pt) |
| AR (2) | AR055191A1 (pt) |
| AU (1) | AU2006301446B2 (pt) |
| BR (1) | BRPI0618399B1 (pt) |
| CA (1) | CA2625681C (pt) |
| CY (1) | CY1119722T1 (pt) |
| DK (1) | DK2860192T3 (pt) |
| ES (1) | ES2653664T3 (pt) |
| HR (1) | HRP20171978T1 (pt) |
| HU (1) | HUE035250T2 (pt) |
| IL (1) | IL190665B (pt) |
| LT (1) | LT2860192T (pt) |
| ME (1) | ME02886B (pt) |
| NO (1) | NO344961B1 (pt) |
| NZ (1) | NZ566915A (pt) |
| PL (1) | PL2860192T3 (pt) |
| PT (1) | PT2860192T (pt) |
| RS (1) | RS56677B1 (pt) |
| RU (1) | RU2425841C2 (pt) |
| SG (1) | SG10201400973XA (pt) |
| SI (1) | SI2860192T1 (pt) |
| TW (1) | TWI428444B (pt) |
| WO (1) | WO2007042309A2 (pt) |
| ZA (1) | ZA200803208B (pt) |
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CN101287764B (zh) * | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| UY32317A (es) | 2008-12-12 | 2010-07-30 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| US8877899B2 (en) * | 2010-09-27 | 2014-11-04 | Morphosys Ag | Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US9238689B2 (en) | 2011-07-15 | 2016-01-19 | Morpho Sys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| SG10201703249PA (en) | 2011-12-21 | 2017-05-30 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| EP2843051B1 (en) * | 2012-04-23 | 2018-06-06 | GeneFrontier Corporation | Anti-human cd69 antibody, and use thereof for medical purposes |
| HRP20171964T1 (hr) * | 2012-09-25 | 2018-02-23 | Morphosys Ag | Kombinacije i njihova upotreba |
| US9486547B2 (en) | 2012-11-05 | 2016-11-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
| CN104937099B (zh) | 2012-11-09 | 2018-03-30 | 基因先端领域株式会社 | 用于治疗癌症的抗adam28抗体 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| CA2909952C (en) * | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US9963515B2 (en) | 2013-04-29 | 2018-05-08 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| JP5892117B2 (ja) * | 2013-07-17 | 2016-03-23 | 横河電機株式会社 | フィールド機器及び通信システム |
| CN103513040B (zh) * | 2013-10-16 | 2015-03-11 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| EP3175289A4 (en) | 2014-08-03 | 2018-04-18 | Pogotec, Inc. | Wearable camera systems and apparatus and method for attaching camera systems or other electronic devices to wearable articles |
| WO2016040294A2 (en) * | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| HK1245171A1 (zh) * | 2014-11-26 | 2018-08-24 | Xencor, Inc. | 结合cd3和cd38的异二聚体抗体 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| PE20171094A1 (es) * | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| US10329358B2 (en) | 2015-03-06 | 2019-06-25 | Genefrontier Corporation | Anti-human membrane-type ADAM28 antibody |
| CN113527495A (zh) | 2015-04-08 | 2021-10-22 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
| US10533057B2 (en) | 2015-05-13 | 2020-01-14 | Morphosys Ag | Treatment for multiple myeloma (MM) |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| CN107708734B (zh) * | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| EP3313441B1 (en) | 2015-06-24 | 2024-02-21 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| CN108699161B (zh) * | 2016-03-04 | 2022-06-03 | 莫佛塞斯公司 | 多发性骨髓瘤中m-蛋白应答的临床评估 |
| JP7103950B2 (ja) | 2016-04-22 | 2022-07-20 | アクセレロン ファーマ インコーポレーテッド | Ａｌｋ７結合性タンパク質及びその使用 |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| RU2019102008A (ru) | 2016-06-28 | 2020-07-28 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| US10478497B2 (en) | 2016-07-20 | 2019-11-19 | Hybrigenics S.A. | Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| US11124577B2 (en) | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| KR102770106B1 (ko) | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| US11780930B2 (en) | 2017-06-08 | 2023-10-10 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| AU2018316521B2 (en) | 2017-08-16 | 2025-01-30 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| JP7299873B2 (ja) * | 2017-08-16 | 2023-06-28 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８抗体 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US20200207867A1 (en) | 2017-09-13 | 2020-07-02 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| EP3692066A2 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| BR112020007751A2 (pt) | 2017-10-25 | 2020-10-20 | Acceleron Pharma Inc. | proteínas de ligação de alk7 e usos das mesmas |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| KR20200076732A (ko) | 2017-11-03 | 2020-06-29 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd38-지시된 키메라 항원 수용체 작제물 |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| MX2020007429A (es) | 2018-01-12 | 2020-10-15 | Takeda Pharmaceuticals Co | Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). |
| WO2019143948A1 (en) | 2018-01-18 | 2019-07-25 | Fred Hutchinson Cancer Research Center | Altering inflammatory states of immune cells in vivo by modulating cellular activation states |
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| WO2019183266A1 (en) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| US12048745B2 (en) | 2018-05-01 | 2024-07-30 | Augusta University Research Institute, Inc. | Methods for detecting and reversing immune therapy resistance |
| WO2019220368A1 (en) | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| JP7637510B2 (ja) | 2018-06-20 | 2025-02-28 | ビバソル， インコーポレイテッド | Ｃｄ３８に結合するバリアント抗体 |
| MA53123A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
| EP3820900A1 (en) | 2018-07-13 | 2021-05-19 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| CN112513087B (zh) | 2018-09-11 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 抗cd38抗体、其抗原结合片段及医药用途 |
| CN109293773B (zh) * | 2018-09-25 | 2020-09-04 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
| MA53920A (fr) | 2018-10-17 | 2021-09-15 | Janssen Biotech Inc | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 |
| WO2020087065A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| CN113015805B (zh) | 2018-11-13 | 2024-12-03 | 詹森生物科技公司 | 抗cd38抗体产生期间的痕量金属的控制 |
| MX2021007047A (es) * | 2018-12-14 | 2021-10-26 | Morphosys Ag | Formulaciones de anticuerpos. |
| CN113614107A (zh) * | 2019-01-23 | 2021-11-05 | Encefa公司 | Cd31竞争剂及其用途 |
| TWI924633B (zh) | 2019-03-15 | 2026-05-11 | 德商莫菲西斯公司 | 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物 |
| EP3993832A4 (en) * | 2019-07-03 | 2023-10-18 | Crystal Bioscience Inc. | ANTI-CD38 ANTIBODIES AND METHOD OF USE THEREOF |
| EP4031166A1 (en) * | 2019-09-18 | 2022-07-27 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
| TWI878355B (zh) | 2019-10-02 | 2025-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| GB201916150D0 (en) | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
| JP7811772B2 (ja) * | 2019-12-05 | 2026-02-06 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
| BR112022011824A2 (pt) | 2019-12-18 | 2022-08-30 | Teneofour Inc | Anticorpos de cadeia pesada que se ligam a cd38 |
| MX2022008050A (es) | 2020-01-16 | 2022-07-27 | Genmab As | Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas. |
| EP4149632A1 (en) | 2020-05-14 | 2023-03-22 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
| CN113861292B (zh) * | 2020-06-30 | 2026-05-12 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
| CN111808193B (zh) * | 2020-06-30 | 2022-04-05 | 源道隆（苏州）医学科技有限公司 | 可结合人cd38的纳米抗体及其应用 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| TW202233668A (zh) | 2020-10-21 | 2022-09-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子 |
| EP4277930A1 (en) | 2021-01-14 | 2023-11-22 | MorphoSys AG | Anti-cd38 antibodies and their uses |
| CN116635422A (zh) * | 2021-01-14 | 2023-08-22 | 莫佛塞斯公司 | 抗cd38抗体及其用途 |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| CN116997570A (zh) * | 2021-03-01 | 2023-11-03 | 莫佛塞斯公司 | 用于治疗抗体介导的移植排斥的抗cd38抗体 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
| EP4376869A1 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| US20230134748A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
| EP4426437A4 (en) | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
| CN116514974A (zh) * | 2022-01-30 | 2023-08-01 | 百奥泰生物制药股份有限公司 | 抗cd28抗体及其应用 |
| WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
| EP4536278A4 (en) | 2022-06-07 | 2026-08-12 | Actinium Pharmaceuticals Inc | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| WO2024013315A1 (en) | 2022-07-15 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| US20250382378A1 (en) | 2022-10-31 | 2025-12-18 | Genmab A/S | Cd38 antibodies and uses thereof |
| IL320562A (en) | 2022-11-02 | 2025-07-01 | Janssen Biotech Inc | Cancer treatment methods |
| WO2024153768A1 (en) | 2023-01-20 | 2024-07-25 | Boehringer Ingelheim International Gmbh | Il-12 fc fusion proteins |
| WO2025231372A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
| US20260070998A1 (en) | 2024-09-10 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors |
| CN119119277B (zh) * | 2024-10-24 | 2025-09-09 | 深圳技术大学 | 一种靶向cd38的纳米抗体、药物组合物及其应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| AU605132B2 (en) * | 1986-01-03 | 1991-01-10 | Consolidated Pharmaceuticals Limited | Melphalan derivatives |
| SU1595902A1 (ru) * | 1988-06-30 | 1990-09-30 | Всесоюзный онкологический научный центр АМН СССР | Штамм гибридных культивируемых клеток животных MUS мUSсULUS L, используемый дл получени моноклональных антител к антигену СД38 кортикальных тимоцитов |
| US5156951A (en) * | 1989-07-13 | 1992-10-20 | Becton Dickinson And Company | Detecting immunological changes in HIV infected patient samples |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
| US6555324B1 (en) | 1993-11-04 | 2003-04-29 | Becton Dickinson & Company | Method to distinguish hematopoietic progenitor cells |
| GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| US20020164788A1 (en) * | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| ATE271128T1 (de) | 1995-05-11 | 2004-07-15 | Applied Research Systems | Inhibitoren der il-6 aktivitaet |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| US5594116A (en) | 1995-11-08 | 1997-01-14 | Promega Corporation | Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay |
| JP4233608B2 (ja) * | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | 自己抗体測定方法 |
| AU770718B2 (en) | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| GB9903664D0 (en) | 1999-02-17 | 1999-04-14 | Isis Innovation | Adjuvant and cell maturation agent |
| JP2000316578A (ja) | 1999-05-12 | 2000-11-21 | Bml Inc | 糖尿病発症危険因子の検出方法 |
| CA2347973C (en) | 1999-07-20 | 2010-06-22 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
| EP1174440A1 (en) * | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| US6955884B2 (en) | 2000-10-17 | 2005-10-18 | Trudeau Institute, Inc. | Methods for identifying compounds that inhibit CD38 activity |
| US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| US6892140B1 (en) | 2000-11-27 | 2005-05-10 | Enteron, Inc. | Immunogenic cancer peptides and uses thereof |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| US20040081981A1 (en) | 2001-01-31 | 2004-04-29 | Toru Egashira | Method of detecting risk factor for onset of diabetes |
| JP4406206B2 (ja) | 2001-04-24 | 2010-01-27 | バイエル コーポレーション | ヒトｔｉｍｐ−１抗体 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP1369431A4 (en) | 2001-10-15 | 2005-01-12 | Kirin Brewery | ANTI-HLA-DR ANTIBODIES |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7553926B2 (en) | 2002-04-23 | 2009-06-30 | Andrea Savarino | Compositions containing anti-HIV peptides and methods for use |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| EP1689435A4 (en) | 2003-10-22 | 2007-10-03 | Univ Rochester | ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| DE602005017246D1 (de) | 2004-02-13 | 2009-12-03 | Boehringer Ingelheim Pharma | Cd38-spleiss-varianten und deren anwendungen |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| CA2604844A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Cancer-related genes |
| TW200745162A (en) * | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN101287764B (zh) * | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| HUE027683T2 (en) | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
| US8435516B2 (en) | 2009-10-12 | 2013-05-07 | Pfizer Inc. | Cancer treatment |
| US8877899B2 (en) * | 2010-09-27 | 2014-11-04 | Morphosys Ag | Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| HRP20171964T1 (hr) * | 2012-09-25 | 2018-02-23 | Morphosys Ag | Kombinacije i njihova upotreba |
| US9486547B2 (en) * | 2012-11-05 | 2016-11-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
| WO2020202527A1 (ja) | 2019-04-04 | 2020-10-08 | オリンパス株式会社 | 画像記録装置 |
| US12491218B2 (en) | 2019-06-30 | 2025-12-09 | Uplift Food Inc | Prebiotic and probiotic cookie preparation |
| US11920830B1 (en) | 2022-11-11 | 2024-03-05 | Russell Dwayne Mcnally | Tool and method for cleaning and draining a water heater |
-
2006
- 2006-10-12 CN CN2006800379242A patent/CN101287764B/zh active Active
- 2006-10-12 PL PL14196972T patent/PL2860192T3/pl unknown
- 2006-10-12 CN CN201310494874.2A patent/CN103554259B/zh active Active
- 2006-10-12 US US12/089,806 patent/US8088896B2/en active Active
- 2006-10-12 KR KR1020137033870A patent/KR101472250B1/ko active Active
- 2006-10-12 PT PT141969725T patent/PT2860192T/pt unknown
- 2006-10-12 WO PCT/EP2006/009889 patent/WO2007042309A2/en not_active Ceased
- 2006-10-12 SI SI200632232T patent/SI2860192T1/en unknown
- 2006-10-12 JP JP2008534940A patent/JP5362359B2/ja active Active
- 2006-10-12 RU RU2008111882/10A patent/RU2425841C2/ru active
- 2006-10-12 BR BRPI0618399-9A patent/BRPI0618399B1/pt active IP Right Grant
- 2006-10-12 CA CA2625681A patent/CA2625681C/en active Active
- 2006-10-12 DK DK14196972.5T patent/DK2860192T3/en active
- 2006-10-12 AR ARP060104476A patent/AR055191A1/es active IP Right Grant
- 2006-10-12 AU AU2006301446A patent/AU2006301446B2/en active Active
- 2006-10-12 NZ NZ566915A patent/NZ566915A/en unknown
- 2006-10-12 EP EP14196972.5A patent/EP2860192B1/en active Active
- 2006-10-12 EP EP17193089.4A patent/EP3284756B1/en active Active
- 2006-10-12 EP EP06806243A patent/EP1945671A2/en not_active Withdrawn
- 2006-10-12 RS RS20171300A patent/RS56677B1/sr unknown
- 2006-10-12 CN CN201510918061.0A patent/CN106434683B/zh active Active
- 2006-10-12 KR KR1020087011301A patent/KR101512853B1/ko active Active
- 2006-10-12 ME MEP-2017-289A patent/ME02886B/me unknown
- 2006-10-12 LT LTEP14196972.5T patent/LT2860192T/lt unknown
- 2006-10-12 SG SG10201400973XA patent/SG10201400973XA/en unknown
- 2006-10-12 KR KR1020157034098A patent/KR20150139636A/ko not_active Ceased
- 2006-10-12 ES ES14196972.5T patent/ES2653664T3/es active Active
- 2006-10-12 CN CN201310495574.6A patent/CN103554260A/zh active Pending
- 2006-10-12 TW TW095137628A patent/TWI428444B/zh active
- 2006-10-12 KR KR1020147020460A patent/KR101574920B1/ko active Active
- 2006-10-12 HU HUE14196972A patent/HUE035250T2/hu unknown
-
2008
- 2008-04-07 IL IL190665A patent/IL190665B/en active IP Right Grant
- 2008-04-11 ZA ZA200803208A patent/ZA200803208B/xx unknown
- 2008-04-25 NO NO20081972A patent/NO344961B1/no unknown
-
2011
- 2011-11-08 US US13/291,473 patent/US8486394B2/en active Active
-
2012
- 2012-11-08 JP JP2012246686A patent/JP5752667B2/ja active Active
-
2013
- 2013-06-14 US US13/918,199 patent/US9193799B2/en active Active
-
2015
- 2015-10-08 US US14/877,958 patent/US10184005B2/en active Active
-
2016
- 2016-07-26 AR ARP160102271A patent/AR105490A2/es not_active Application Discontinuation
-
2017
- 2017-12-19 CY CY20171101331T patent/CY1119722T1/el unknown
- 2017-12-20 HR HRP20171978TT patent/HRP20171978T1/hr unknown
-
2018
- 2018-09-07 US US16/125,307 patent/US11059902B2/en active Active
-
2021
- 2021-06-09 US US17/343,163 patent/US11939395B2/en active Active
-
2024
- 2024-01-22 US US18/418,804 patent/US20240309109A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| CY1123708T1 (el) | Αντισωματα που συνδεονται προς τον ανθρωπινο προσδετη 1 (pd-l1) προγραμματισμενου θανατου | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| BRPI0819909B8 (pt) | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica | |
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| BR112013004579A2 (pt) | proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9 | |
| EA201101516A1 (ru) | Антитела, специфические для кадгерина-17 | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| MX2010007406A (es) | Anticuerpos anti-factor inhibidor de migracion de macrofago (mif). | |
| CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| BR112016003369A2 (pt) | diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| CY1116458T1 (el) | Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων | |
| NO20082559L (no) | Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer | |
| BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
| MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
| BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
| BRPI0808940A8 (pt) | anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor | |
| EA201892184A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора | |
| AR055191A1 (es) | Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano | |
| PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| ZA202201464B (en) | Anti-tigit antibodies and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: MORPHOSYS AG (DE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/10/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |